Albert Bourla bagged $21M in year marked by generics spinoff, colossal R&D effort for Covid-19 vaccine
Among the largest drugmakers, Pfizer had one of the busiest years of its peers, including racing to market with its BioNTech-partnered Covid-19 shot and successfully spinning out its generic Upjohn unit. For two-year CEO Albert Bourla, all that work meant more money in his pocket.
Bourla earned a $21 million pay package in 2020, a roughly 17% jump from the $17.9 million he made the prior year. Of that, the biggest bumps were options awards — Bourla took home $6.78 million in 2020 compared with $6.08 million the year before — and non-equity incentives, of which Bourla snared $5.5 million. The year before, that figure was $3.63 million.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.